Positive News SentimentPositive NewsNASDAQ:BTMD biote (BTMD) Stock Price, News & Analysis $6.23 -0.01 (-0.16%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$6.13▼$6.3250-Day Range$5.33▼$8.3652-Week Range$3.65▼$8.44Volume172,377 shsAverage Volume166,694 shsMarket Capitalization$386.48 millionP/E Ratio56.64Dividend YieldN/APrice Target$8.39 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get biote alerts: Email Address biote MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside34.6% Upside$8.39 Price TargetShort InterestHealthy3.86% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares$86,116 Sold Last QuarterProj. Earnings Growth9.62%From $0.52 to $0.57 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.71 out of 5 starsMedical Sector211th out of 910 stocksMedicinals & Botanicals Industry2nd out of 12 stocks 3.5 Analyst's Opinion Consensus Ratingbiote has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst Coveragebiote has received no research coverage in the past 90 days.Read more about biote's stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted3.86% of the float of biote has been sold short.Short Interest Ratio / Days to Coverbiote has a short interest ratio ("days to cover") of 4.5.Change versus previous monthShort interest in biote has recently decreased by 9.38%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend Yieldbiote does not currently pay a dividend.Dividend Growthbiote does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BTMD. Previous Next 2.7 News and Social Media Coverage News Sentimentbiote has a news sentiment score of 1.92. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for biote this week, compared to 1 article on an average week.MarketBeat FollowsOnly 1 people have added biote to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, biote insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $86,116.00 in company stock.Percentage Held by Insiders13.90% of the stock of biote is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 21.68% of the stock of biote is held by institutions.Read more about biote's insider trading history. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for biote are expected to grow by 9.62% in the coming year, from $0.52 to $0.57 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of biote is 56.64, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 127.87.Price to Earnings Ratio vs. SectorThe P/E ratio of biote is 56.64, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 115.64.Read more about biote's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyWar on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.One company holds a near-total monopoly on it. About biote Stock (NASDAQ:BTMD)biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female. The company was founded in 2012 and is headquartered in Irving, Texas.Read More BTMD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BTMD Stock News HeadlinesAugust 10, 2024 | seekingalpha.combiote Corp. (BTMD) Q2 2024 Earnings Call TranscriptAugust 9, 2024 | markets.businessinsider.comRoth MKM Keeps Their Buy Rating on biote (BTMD)September 7, 2024 | Sasco Gold LLC (Ad)Say Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." I believe the American people deserve to control the fate of their own life savings which is why I had my team put together our latest guide to protect your hard-earned wealth before it's too late... August 9, 2024 | finance.yahoo.comBiote Reports Second Quarter 2024 Financial ResultsAugust 7, 2024 | markets.businessinsider.comHere's what to expect from biote A's earningsJuly 25, 2024 | finance.yahoo.comBiote Schedules Second Quarter 2024 Financial Results Release and Conference CallJune 20, 2024 | businesswire.comBiote Announces $60 Million Agreement to Repurchase 8.3 Million Shares and Cancel Approximately 4.0 Million Earnout SharesMay 9, 2024 | finance.yahoo.combiote Corp. (PNK:BTMD) Q1 2024 Earnings Call TranscriptSeptember 7, 2024 | Sasco Gold LLC (Ad)Say Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." I believe the American people deserve to control the fate of their own life savings which is why I had my team put together our latest guide to protect your hard-earned wealth before it's too late... May 7, 2024 | msn.comBTMD Stock Earnings: Biote Misses EPS, Beats Revenue for Q1 2024May 7, 2024 | businesswire.comBiote Reports First Quarter 2024 Financial ResultsMay 7, 2024 | seekingalpha.comEsperion Therapeutics beats top-line and bottom-line estimates; reaffirms FY24 outlookApril 29, 2024 | finance.yahoo.comBiote Announces Definitive Settlement with FounderApril 23, 2024 | businesswire.comBiote Schedules First Quarter 2024 Financial Results Release and Conference CallMarch 25, 2024 | msn.comEsperion stock jumps 18% in wake of FDA label expansionsMarch 18, 2024 | markets.businessinsider.comPharvaris Buy Rating Affirmed Amid Promising Phase 3 HAE Trial ProspectsMarch 14, 2024 | marketwatch.comBiote Soars 22% With Expected Acceleration in 2H 2024 SalesMarch 13, 2024 | finance.yahoo.combiote Corp. (PNK:BTMD) Q4 2023 Earnings Call TranscriptSee More Headlines Receive BTMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for biote and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/08/2024Today9/07/2024Next Earnings (Estimated)11/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medicinals & botanicals Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BTMD CUSIPN/A CIK1819253 Webbiote.com Phone844-604-1246Fax212-616-9601Employees194Year FoundedN/APrice Target and Rating Average Stock Price Target$8.39 High Stock Price Target$9.00 Low Stock Price Target$6.55 Potential Upside/Downside+34.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)$0.11 Trailing P/E Ratio56.64 Forward P/E Ratio11.98 P/E GrowthN/ANet Income$3.32 million Net Margins3.67% Pretax Margin10.27% Return on Equity-20.92% Return on Assets10.29% Debt Debt-to-Equity RatioN/A Current Ratio1.34 Quick Ratio0.92 Sales & Book Value Annual Sales$187.23 million Price / Sales2.06 Cash Flow$0.49 per share Price / Cash Flow12.62 Book Value($2.61) per share Price / Book-2.39Miscellaneous Outstanding Shares62,036,000Free Float53,413,000Market Cap$386.48 million OptionableNot Optionable Beta0.94 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Marc D. Beer (Age 59)Executive Chairman Comp: $470.18kMs. Teresa S. Weber (Age 71)CEO & Director Comp: $1.06MMs. Mary Elizabeth Conlon (Age 43)VP of Business Development, General Counsel & Corporate Secretary Comp: $552.36kMs. Mary J. Puncochar (Age 60)Head of Strategic Sales & Business Analytics Comp: $465.47kMr. Robert C. Peterson (Age 47)Chief Financial Officer Mr. John J. Olsen (Age 67)Chief Information Officer Mr. James Elliott Gibbs IIChief People OfficerMr. Richard Kevin Key (Age 53)Chief Digital Officer Mr. Jade Beutler (Age 61)Head of Nutraceuticals Dr. Cory Rice D.O.Chief Clinical Advisor & Member of Medical Advisory BoardMore ExecutivesKey CompetitorsAdTheorentNASDAQ:ADTHDecarbonization Plus Acquisition Co. IVNASDAQ:DCRDOPAL FuelsNASDAQ:OPALAvadel PharmaceuticalsNASDAQ:AVDLNewAmsterdam PharmaNASDAQ:NAMSView All CompetitorsInsiders & InstitutionsThe Manufacturers Life Insurance Company Bought 11,271 shares on 8/15/2024Ownership: 0.018%Dimensional Fund Advisors LPBought 600,956 shares on 8/9/2024Ownership: 1.064%Renaissance Technologies LLCBought 138,200 shares on 8/9/2024Ownership: 0.311%GDS Wealth ManagementBought 57,789 shares on 8/9/2024Ownership: 0.093%WINTON GROUP LtdBought 3,124 shares on 8/9/2024Ownership: 0.077%View All Insider TransactionsView All Institutional Transactions BTMD Stock Analysis - Frequently Asked Questions How have BTMD shares performed this year? biote's stock was trading at $4.94 on January 1st, 2024. Since then, BTMD stock has increased by 26.1% and is now trading at $6.23. View the best growth stocks for 2024 here. How were biote's earnings last quarter? biote Corp. (NASDAQ:BTMD) announced its earnings results on Thursday, August, 8th. The company reported $0.14 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.09 by $0.05. The business had revenue of $49.17 million for the quarter, compared to analysts' expectations of $50.40 million. biote had a net margin of 3.67% and a negative trailing twelve-month return on equity of 20.92%. Who are biote's major shareholders? biote's top institutional shareholders include Dimensional Fund Advisors LP (1.06%), Renaissance Technologies LLC (0.31%), Skylands Capital LLC (0.26%) and Bank of New York Mellon Corp (0.15%). Insiders that own company stock include Roystone Capital Management Lp, Mary Elizabeth Conlon, Robert Charles Peterson and Samar Jagat Kamdar. View institutional ownership trends. How do I buy shares of biote? Shares of BTMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:BTMD) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding biote Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share biote With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
